Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13873451 | 0.89 | ALDH1A1 (0.56) | ALDH1A1KMT2AMAPTCA12CA9 | |
| SCHEMBL5998859 | 0.88 | TNF (0.43) | ALDH1A1KMT2AMAPTMEN1POLB | |
| SCHEMBL5998387 | 0.86 | ALDH1A1 (0.49) | ALDH1A1KMT2AMAPTMEN1 | |
| SCHEMBL5998663 | 0.86 | KMT2A (0.42) | ALDH1A1KMT2AMAPTNPC1MEN1 | |
| SCHEMBL8431420 | 0.85 | CA12 (0.53) | ALDH1A1KMT2ACA12CA9MEN1 | |
| SCHEMBL29740350 | 0.85 | CA12 (0.53) | ALDH1A1KMT2ACA12CA9MEN1 | |
| SCHEMBL5997284 | 0.85 | TNF (0.43) | ALDH1A1KMT2AMAPTNPC1MEN1 | |
| SCHEMBL5997416 | 0.84 | NPC1 (0.46) | ALDH1A1KMT2ACA12CA9NPC1 | |
| SCHEMBL5998270 | 0.84 | HDAC4 (0.42) | ALDH1A1KMT2AMAPTNPC1MEN1 | |
| SCHEMBL5997204 | 0.84 | FGFR1 (0.41) | ALDH1A1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114774491-B | Method for preparing (2S, 3R) -2- (phthalimidomethyl) -3-hydroxybutyrate | 湖州颐盛生物科技有限公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-114774491-A | Process for preparing (2S,3R) -2- (phthalimidomethyl) -3-hydroxybutyrate | 湖州颐盛生物科技有限公司 | 2022-07-22 | — | — | CN | disclosed |
| US-7094908-B2 | Reduction of carbonyl compounds using the carbonyl reductase of Kluyveromyces marxianus | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2006-08-22 | — | — | US | disclosed |
| US-20030139464-A1 | Reduction of carbonyl compounds using the carbonyl reductase of kluyveromyces marxianus | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139464-A1 | Reduction of carbonyl compounds using the carbonyl reductase of kluyveromyces marxianus | CBR1, CBR3, DCXR | ALDH1A1 216/4885KMT2A 1280/4885MAPT 3262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.